CD274 and neoplasm: A pre-clinical study observed in murine models an increase of PD-L1 expression and T-cytotoxic infiltration, decreased T-cell exhaustion and tumor shrinkage when either olaparib (a PARP inhibitor) or prexasertib (a checkpoint kinase 1 inhibitor) were associated to an anti-PD-L1 agent [43].